ZIOPHARM Oncology Inc (ZIOP) Scheduled to Post Quarterly Earnings on Monday
ZIOPHARM Oncology Inc (NASDAQ:ZIOP) is set to issue its quarterly earnings data after the market closes on Monday, November 6th. Analysts expect the company to announce earnings of ($0.13) per share for the quarter.
ZIOPHARM Oncology (NASDAQ:ZIOP) last issued its earnings results on Monday, July 31st. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.13). The firm had revenue of $1.60 million during the quarter, compared to the consensus estimate of $1.66 million. The company’s quarterly revenue was down 5.9% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.01) EPS. On average, analysts expect ZIOPHARM Oncology to post $-0.55 EPS for the current fiscal year and $-0.58 EPS for the next fiscal year.
Shares of ZIOPHARM Oncology Inc (NASDAQ ZIOP) traded up 1.26% on Monday, hitting $4.83. 1,181,210 shares of the stock traded hands. The stock’s 50 day moving average price is $5.89 and its 200 day moving average price is $6.14. The stock’s market cap is $679.25 million. ZIOPHARM Oncology Inc has a 52-week low of $4.40 and a 52-week high of $7.88.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/30/ziopharm-oncology-inc-ziop-scheduled-to-post-quarterly-earnings-on-monday.html.
A number of research firms have recently weighed in on ZIOP. BidaskClub cut shares of ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a report on Monday, August 14th. ValuEngine cut shares of ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a report on Friday, September 15th. Finally, HC Wainwright set a $10.00 price target on shares of ZIOPHARM Oncology and gave the company a “buy” rating in a report on Tuesday, August 1st. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $16.50.
About ZIOPHARM Oncology
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.